|
KMID : 0043320080310010067
|
|
Archives of Pharmacal Research
2008 Volume.31 No. 1 p.67 ~ p.74
|
|
|
Auranofin Inhibits Overproduction of Pro-Inflammatory Cytokines, Cyclooxygenase Expression and PGE2 Production in Macrophages
|
|
Han Shin-Ha
Kim Kwang-Hee
Kim Hyun-Yul
Kwon Jeung-Hak
Kim Kyung-Jae
Ha Nam-Joo
Lee Young-Hee
Lee Chong-Kil
Lee Sang-Jin
Song Yung-Cheon
|
|
|
Abstract
|
|
|
|
Auranofin (AF), a gold compound, is an orally active therapeutic agent used to treat rheumatoid arthritis (RA), a self-perpetuating inflammatory disease. RA is characterized by autoimmune-mediated proliferation of synovial cells that leads to inflammation, pain, and swelling in most major joints. However, the mechanism as to how AF relieves RA symptoms has not been fully elucidated. The object of this study was to examine the ability of AF to immunomodulate macrophages as antigen presenting cells (APCs). Macrophages are recognized as playing an important role in the pathogenesis of RA, in that there is a relative abundance of macrophagederived cytokines, such as tumor necrosis factor- α(TNFα),interlcukin-1β (IL-1β) and interleukin-6 (IL-6) in rheumatoid synovium. In this work, we tested whether AF (2.5-20 mM) could inhibit inflammatory activity in the macrophage cell line RAW 264.7. AF decreased production of nitric oxide (NO) and the pro-inflammatory cytokines,TNF- α,IL-1β) and IL-6 in macrophages. Furthermore, AF inhibited cyclooxygenase-2 (COX-2)-dependent prostaglandin E2 (PGE2) production in a concentration-dependent manner. In conclusion, these findings may provide an explanation for the clinical effects of AF in patients with RA.
|
|
|
KEYWORD
|
|
|
Auranofin, Anti-inflammation, Nitric oxide, Pro-inflammatory cytokines, Cyclooxygenase-2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|